Cu-64 sartate

Cu-64 SARTATE is a next-generation, highly targeted copper-based radiopharmaceutical developed for both diagnostic imaging and potential therapy of cancers expressing somatostatin receptors, particularly neuroblastoma and neuroendocrine tumors (NETs). It consists of the peptide octreotate linked to Clarity Pharmaceuticals' proprietary SAR Technology chelator, which securely binds copper radioisotopes such as Cu‑64. The drug targets somatostatin receptor 2 (SSTR2), which is overexpressed in many neuroendocrine tumors and most cases of neuroblastoma. Cu‑64 SARTATE is used primarily for PET imaging due to the favorable half-life and stability provided by the SAR chelator, allowing flexible imaging time points compared to other agents like Ga‑68. The mechanism involves binding to SSTR2 on tumor cells, enabling precise localization via PET scan. Clarity Pharmaceuticals has received FDA Orphan Drug Designation for Cu‑64 SARTATE in neuroblastoma[1][4][6].

Brand names

SARTATE

Other names

ucasaeotide dasaroxetan cu-64